Business Standard

Analysts' corner

Ranbaxy Laboratories & Havells India

Related News

RANBAXY LABORATORIES
Reco price/date: Rs 552/September 3
Current/target price: Rs 568.55/Rs 450
After the launch of Actos, Ranbaxy has given 14 per cent absolute returns, outperforming the market and the healthcare index by three per cent. However, the downward earnings revisions show the initial euphoria during the launch was not sustained. Also, except Lipitor, stocks have given negative returns in a six-month period. The trade recorded in a month was reversed in a two-quarter timeframe. Though the launch of Actos removes the overhang of the result of forfeiting exclusivities, analysts believe the competitive dynamics of the product launch would be tougher than initially estimated. They say this could lead to a downward estimate revision, as seen earlier. Maintain 'Sell'.

Antique Stock Broking

HAVELLS INDIA
Reco price/date: Rs 550/September 3
Current/target price: Rs 555.25/Rs 680
The stock underperformed the Sensex by 6.0 per cent during the past three months. It is now trading at 12.1 times the 2013-14 estimated price/earnings ratio, which analysts believe is an attractive valuation. Analysts see steady growth in a tough operating environment, a strong balance sheet, improving free cash generation and a potential rise in the dividend payout as strong stock price drivers. JP Morgan thinks the recent guidance cut for Sylvania margins is priced in, and recent forex trends have become favourable. This could help alleviate concern on a further downside to Sylvania's margins. JP Morgan has raised its FY14 estimated earnings per share five per cent. Upgrade to 'Overweight' from 'Neutral'.

JP Morgan

Read more on:   
|

Analysts' corner

Ranbaxy Laboratories & Havells India

After the launch of Actos, Ranbaxy has given 14 per cent absolute returns, outperforming the market and the healthcare index by three per cent. However, the downward earnings revisions show the initial euphoria during the launch was not sustained. Also, except Lipitor, stocks have given negative returns in a six-month period. The trade recorded in a month was reversed in a two-quarter timeframe. Though the launch of Actos removes the overhang of the result of forfeiting exclusivities, analysts believe the competitive dynamics of the product launch would be tougher than initially estimated. They say this could lead to a downward estimate revision, as seen earlier. Maintain 'Sell'.

RANBAXY LABORATORIES
Reco price/date: Rs 552/September 3
Current/target price: Rs 568.55/Rs 450
After the launch of Actos, Ranbaxy has given 14 per cent absolute returns, outperforming the market and the healthcare index by three per cent. However, the downward earnings revisions show the initial euphoria during the launch was not sustained. Also, except Lipitor, stocks have given negative returns in a six-month period. The trade recorded in a month was reversed in a two-quarter timeframe. Though the launch of Actos removes the overhang of the result of forfeiting exclusivities, analysts believe the competitive dynamics of the product launch would be tougher than initially estimated. They say this could lead to a downward estimate revision, as seen earlier. Maintain \'Sell\'.

Antique Stock Broking

HAVELLS INDIA
Reco price/date: Rs 550/September 3
Current/target price: Rs 555.25/Rs 680
The Havells India stock underperformed the Sensex by 6.0 per cent during the past three months. It is now trading at 12.1 times the 2013-14 estimated price/earnings ratio, which analysts believe is an attractive valuation. Analysts see steady growth in a tough operating environment, a strong balance sheet, improving free cash generation and a potential rise in the dividend payout as strong stock price drivers. JP Morgan thinks the recent guidance cut for Sylvania margins is priced in, and recent forex trends have become favourable. This could help alleviate concern on a further downside to Sylvania\'s margins. JP Morgan has raised its FY14 estimated earnings per share five per cent. Upgrade to \'Overweight\' from \'Neutral\'.

JP Morgan

image

Read More

Fund managers divided on high beta preference

Riding high on the crest of the reforms wave, the markets touched their highest closing levels since July 2011 during the week under review ...

Recommended for you

Quick Links

Market News

UltraTech Cement, Century Textiles up 5%

At 1515 hours, UltraTech Cement was trading at Rs 2,943, while Century Textiles and Industries at Rs 639 on the NSE.

Larsen & Toubro extends gain on order win

The was stock up nearly 3% at Rs 1,722, extending its Friday's 2.7% gain on the National Stock Exchange.

Sensex zooms over 400 points; Nifty above 8,450

By 13:52PM, the 30-share Sensex is higher by 430 points at 27,888 and the Nifty has gained 122 points at 8,463

Telecom shares rebound; Idea, Bharti gain over 3%

Idea Cellular surged nearly 5% to Rs 179, while Bharti Airtel up 3.4% at Rs 389 on the Bombay Stock Exchange.

Tech Mahindra hits three-month low

The stock was down 3% at Rs 625, its lowest level since December 29, 2014, on the National Stock Exchange.

 

Back to Top